The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs' counsel in the product liability litigation. They include drafts and other documents taken out of context, which therefore are incomplete and misleading.

Pfizer Inc. (NYSE: PFE) announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children.

The U.S. Food and Drug Administration (FDA) posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate).

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases.

Nycomed announced that the European Commission has granted marketing authorisation for Daxas® (roflumilast) in the European Union. Daxas® is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that has been developed by Nycomed for the treatment of COPD, a progressive, life-threatening lung disease.

AstraZeneca and MRC Technology, the commercialisation company for the UK's Medical Research Council, announced a new strategic collaboration to share access to their collections of compounds to aid the search for potential new treatments for serious diseases.